Biological Functional Relevance of Asymmetric Dimethylarginine (ADMA) in Cardiovascular Disease

International Journal of Molecular Sciences

Sara Franceschelli¹  Alessio Ferrone¹  Mirko Pesce¹  Graziano Riccioni² 

[1] Department of Medicine and Science of Aging, University G. D’Annunzio-Chieti, Chieti 66100, Italy; E-Mails:;Intensive Cardiology Care Unit, San Camillo de Lellis Hospital, San Severo (FG) 71016, Italy; E-Mail:

关键词: ADMA;    nitric oxide;    cardiovascular disease;   

DOI  :  10.3390/ijms141224412

来源: mdpi

【 摘 要 】

There is growing evidence that increased levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) may contribute to endothelial dysfunction. Studies in animal models as well as in humans have suggested that the increase in ADMA occurs at a time when vascular disease has not yet become clinically evident. ADMA competitively inhibits NO elaboration by displacing l-arginine from NO synthase. In a concentration-dependent manner, it thereby interferes not only with endothelium-dependent, NO-mediated vasodilation, but also with other biological functions exerted by NO. The upshot may be a pro-atherogenic state. Recently, several studies have investigated the effect of various therapeutical interventions on ADMA plasma concentrations.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland